Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
20% albumin versus 4% albumin for fluid bolus therapy in critically ill adults with low blood volume states
ACTRN12615000349549Phase 4Completed
- Sponsor
- Austin Health
- Start
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of albumin (human) in hypovolemia and critical illness (2 arms), sponsored by Austin Health. Primary endpoint: Administered volume of fluid for resuscitation. Started Jul 2015; status: completed.
02
Drugs
albumin (human)
03
Conditions
hypovolemiacritical illness
Beyond the preview
Go deeper on ACTRN12615000349549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000349549.